<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sulfasalazine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sulfasalazine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sulfasalazine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11062" href="/d/html/11062.html" rel="external">see "Sulfasalazine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12817" href="/d/html/12817.html" rel="external">see "Sulfasalazine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F223903"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Azulfidine;</li>
<li>Azulfidine EN-tabs</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868310"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>PMS-Sulfasalazine;</li>
<li>Salazopyrin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F223946"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        5-Aminosalicylic Acid Derivative;</li>
<li>
                        Antirheumatic, Disease Modifying</li></ul></div>
<div class="block doa drugH1Div" id="F223907"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62637659-f98d-4a3f-aec5-dbd1f84dc2b2">Ankylosing spondylitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ankylosing spondylitis (off-label use)</b>: <b>Oral:</b> Immediate and delayed release: Initial: 500 mg once daily; may increase up to 2 to 3 g/day in divided doses; if intolerance occurs, decrease dose by 500 mg each week as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21630245','lexi-content-ref-10555027','lexi-content-ref-7748217']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21630245','lexi-content-ref-10555027','lexi-content-ref-7748217'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e699368-9d16-4ba6-bdd0-4818466239c6">Crohn disease, mild to moderately active</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease, mild to moderately active (off-label use):</b>
<b>Oral:</b> Immediate and delayed release: 3 to 6 g/day in divided doses for up to 16 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508','lexi-content-ref-17877506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508','lexi-content-ref-17877506'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bfcea56-f4f1-4785-9277-8d2c90e99a99">Psoriatic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis (off-label use):</b>
<b>Oral:</b> Immediate and delayed release: Initial: 500 mg once daily; may increase up to 2 to 3 g/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8961906','lexi-content-ref-10555027','lexi-content-ref-8587078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8961906','lexi-content-ref-10555027','lexi-content-ref-8587078'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an alternative to methotrexate in disease-modifying antirheumatic drug (DMARD)–naive patients with moderate to high disease activity, or as adjunctive therapy in patients whose treatment targets have not been met despite maximally tolerated methotrexate therapy. In DMARD-naive patients with low disease activity, sulfasalazine may be used as an alternative to hydroxychloroquine for initial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34101387','lexi-content-ref-31969328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34101387','lexi-content-ref-31969328'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Delayed release: Initial: 500 mg once or twice daily; increase by 500 mg each week up to a maintenance dose of 1 g twice daily. May increase further to a maximum of 3 g/day if response to 2 g/day is inadequate after 12 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f3504104-5393-4688-8e87-33480a9459f0">Ulcerative colitis, mildly to moderately active</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis, mildly to moderately active (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserved for patients who cannot tolerate preferred agents; if used, may have additional benefits in patients who have concurrent inflammatory arthritis. Supplement folic acid during therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30576644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30576644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Induction of remission:</b>
<b>Oral:</b> Immediate and delayed release: 3 to 4 g/day in 3 to 4 divided doses; may initiate at 1 to 2 g/day to improve GI tolerance. Doses &gt;4 g/day may increase the risk of toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6105118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6105118'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance of remission:</b>
<b>Oral:</b> Immediate and delayed release: 2 to 4 g/day in 3 to 4 divided doses once endoscopic exam confirms improvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30840605','lexi-content-ref-6105118','lexi-content-ref-4150435','lexi-content-ref-21407188']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30840605','lexi-content-ref-6105118','lexi-content-ref-4150435','lexi-content-ref-21407188'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment:</b> If intolerance occurs (eg, GI upset, headache, hematologic toxicity, rash), reduce dosage by 50% and gradually increase to target dose over several days. If intolerance persists, stop therapy for 5 to 7 days and reintroduce at a lower daily dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Desensitization regimen:</i> For patients who may be sensitive to treatment, it is suggested to start with a total dose of 50 to 250 mg daily and double it every 4 to 7 days until the desired therapeutic level is achieved. Discontinue if symptoms of sensitivity occur. Do not attempt in patients with a history of agranulocytosis or those who have had a previous anaphylactoid reaction on sulfasalazine therapy</p></div>
<div class="block dora drugH1Div" id="F50990417"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Use with caution along with appropriate monitoring of kidney function in patients with kidney impairment or on dialysis, as prompt identification and management of acute kidney injury is key (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17243140','lexi-content-ref-15188168','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17243140','lexi-content-ref-15188168','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Ensure adequate hydration in order to prevent crystalluria and stone formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Immediate- or delayed-release tablets may be used based on required dose and dosage form availability.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Kidney impairment prior to treatment initiation:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Inflammatory bowel disease (Crohn disease, ulcerative colitis): Oral:</b> Data on the safety of sulfasalazine treatment in patients with preexisting kidney disease is lacking. It may be reasonable to avoid use, if possible, in patients with preexisting impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17243140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17243140'])">Ref</a></span>). If necessary, use with caution and utilize the lowest effective dose; monitor kidney function frequently, especially during flares of inflammatory bowel disease, which could precipitate dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Rheumatic conditions (eg, arthritis, ankylosing spondylitis, psoriatic arthritis): Oral:</b> Initiate therapy at the low end of the dosage range; gradually titrate based on tolerability and response, not to exceed the usual maximum recommended dose for patients with normal kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Sulfasalazine is not dialyzable; sulfapyridine metabolite is dialyzable (62%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24252022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24252022'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Inflammatory bowel disease (Crohn disease, ulcerative colitis): Oral:</b> Data on the safety of sulfasalazine treatment in patients with end-stage kidney disease (ESKD) is lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17243140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17243140'])">Ref</a></span>). Use with caution and utilize the lowest effective dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Rheumatic conditions (eg, arthritis, ankylosing spondylitis, psoriatic arthritis): Oral:</b> Initial: 250 to 500 mg once daily; gradually titrate based on tolerability and response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24252022','lexi-content-ref-22080212','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24252022','lexi-content-ref-22080212','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Doses up to 1 g/day have been well tolerated in patients with ESKD receiving hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24252022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24252022'])">Ref</a></span>); there is no efficacy or safety data available for doses &gt;1 g/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Sulfasalazine unlikely to be dialyzed (&gt;99% protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); dialyzability of sulfapyridine metabolite unknown (has not been studied):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Inflammatory bowel disease (Crohn disease, ulcerative colitis): Oral:</b> Data on the safety of sulfasalazine treatment in patients with ESKD is lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17243140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17243140'])">Ref</a></span>). Use with caution and utilize the lowest effective dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Rheumatic conditions (eg, arthritis, ankylosing spondylitis, psoriatic arthritis): Oral:</b> Initial: 250 to 500 mg once daily; gradually titrate based on tolerability and response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Doses up to 1 g/day have been well tolerated in patients with ESKD receiving hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24252022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24252022'])">Ref</a></span>); there is no efficacy or safety data available for doses &gt;1 g/day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Nephrotoxicity during treatment:</b></i> Nephrotoxicity is most often due to acute or chronic interstitial nephritis, which may occur within the first 12 months or after several years. Interstitial nephritis is idiosyncratic and not dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17243140','lexi-content-ref-15188168']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17243140','lexi-content-ref-15188168'])">Ref</a></span>). Acute kidney injury due to sulfasalazine-induced crystalluria has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21982969','lexi-content-ref-28669550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21982969','lexi-content-ref-28669550'])">Ref</a></span>). Permanently discontinue therapy in patients who experience sulfasalazine-induced nephrotoxicity. Additional measures (eg, corticosteroids, hydration) may be necessary depending on the underlying pathology of the kidney injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17243140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17243140'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987573"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with extreme caution.</p></div>
<div class="block doe drugH1Div" id="F223908"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F223926"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12817" href="/d/html/12817.html" rel="external">see "Sulfasalazine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9117d6e1-33df-4646-bf4f-7e3751815245">Inflammatory bowel disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inflammatory bowel disease (eg, ulcerative colitis; Crohn disease):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing</i>: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction: Crohn disease, ulcerative colitis: Oral: 40 to 70 mg/kg/day in 3 to 6 divided doses; in some cases, higher induction doses up to 100 mg/kg/day may be required; maximum daily dose: 4,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30044357','lexi-content-ref-22516861','lexi-content-ref-20081543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30044357','lexi-content-ref-22516861','lexi-content-ref-20081543'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Ulcerative colitis: Oral: 30 to 70 mg/kg/day in 3 to 6 divided doses; maximum daily dose: 4,000 mg/<b>day</b>; effective induction dose should be transitioned as the initial maintenance dose; may consider dose reduction once remission sustained for several months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30044357','lexi-content-ref-20081543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30044357','lexi-content-ref-20081543'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-SalazopyrinCAN.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-SalazopyrinCAN.2'])">Ref</a></span>): Children ≥25 kg and Adolescents: <b>Note:</b> Consider dose reduction or use of enteric-coated tablet in patients experiencing adverse gastrointestinal effects with uncoated tablet.</p>
<p style="text-indent:-2em;margin-left:6em;">Acute attacks:</p>
<p style="text-indent:-2em;margin-left:8em;">25 to &lt;35 kg: Oral: 500 mg 3 times daily</p>
<p style="text-indent:-2em;margin-left:8em;">35 to 50 kg: Oral: 1,000 mg 2 to 3 times daily</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance of remission:</p>
<p style="text-indent:-2em;margin-left:8em;">25 to &lt;35 kg: Oral: 500 mg 2 times daily</p>
<p style="text-indent:-2em;margin-left:8em;">35 to 50 kg: Oral: 500 mg 2 to 3 times daily</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bfa6a19-11be-4097-9456-7c7ce2ad756d">Juvenile idiopathic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis:</b> Children and Adolescents 6 to 16 years: Oral: Enteric-coated tablet: 30 to 50 mg/kg/day in 2 divided doses; maximum daily dose: 2,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21452260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21452260'])">Ref</a></span>); <b>Note:</b> Although it is an FDA-labeled indication, the use of sulfasalazine for treatment of JIA is not included as a therapeutic option by experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24092554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24092554'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2a5fa63f-a7d5-49a2-8908-0c814a31faaf">Desensitization regimen</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Desensitization regimen</b>: Children ≥6 years and Adolescents: For patients who may be sensitive to treatment, it is suggested to start with a lower total dose, for example when treating inflammatory bowel disease; lower initial doses of 50 to 250 mg daily is suggested (usual is 1,500 to 3,000 mg/day) and double it every 4 to 7 days until the desired dose is achieved. Discontinue if symptoms of sensitivity occur. Do not attempt in patients with a history of agranulocytosis or those who have had a previous anaphylactoid reaction on sulfasalazine therapy.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51160245"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with extreme caution.</p></div>
<div class="block dohp drugH1Div" id="F51160246"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with extreme caution.</p></div>
<div class="block arsc drugH1Div" id="F56412873"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Blood dyscrasias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Various blood dyscrasias have been reported, including <b>agranulocytosis</b>, <b>aplastic anemia</b>, <b>hemolytic anemia</b>, <b>leukopenia</b>, and immune<b> thrombocytopenia</b>, often as part of a multisystemic disease (<b>drug reaction with eosinophilia and systemic symptoms</b> [DRESS]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25854308','lexi-content-ref-27025798','lexi-content-ref-1358622','lexi-content-ref-27778097','lexi-content-ref-12235076','lexi-content-ref-10775222','lexi-content-ref-12795783','lexi-content-ref-28762467']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25854308','lexi-content-ref-27025798','lexi-content-ref-1358622','lexi-content-ref-27778097','lexi-content-ref-12235076','lexi-content-ref-10775222','lexi-content-ref-12795783','lexi-content-ref-28762467'])">Ref</a></span>). Although most cases resolve upon drug discontinuation, there are reports of fatal agranulocytosis associated with sulfasalazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12235076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12235076'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immune thrombocytopenia may occur due to hapten-dependent antibodies, platelet-reactive autoantibodies or drug-dependent antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17551063','lexi-content-ref-27778097']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17551063','lexi-content-ref-27778097'])">Ref</a></span>). Agranulocytosis is a host immune response to the reactive metabolite of sulfasalazine, namely sulfapyridine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28762467']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28762467'])">Ref</a></span>). Dose-related; most cases of leukopenia may be dose-related.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; symptoms usually develop within first 3 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28762467']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28762467'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• G6PD deficiency: Limited data to support an association between sulfasalazine and development of hemolytic anemia in G6PD-deficient patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20701405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20701405'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Agranulocytosis is associated with HLA-B*08:01 and HLA-A*31:01 in European patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28762467']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28762467'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea</b>, <b>vomiting</b>, <b>diarrhea</b>, and <b>abdominal pain</b> are commonly associated with sulfasalazine and may lead to drug discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2874863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2874863'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; increased blood concentration of active metabolite of sulfasalazine (sulfapyridine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2874863','lexi-content-ref-20227029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2874863','lexi-content-ref-20227029'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; nausea occurs within first few days of initiation or dose increase and is usually transient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9133974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9133974'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Increased GI intolerance with uncoated tablets (use of enteric-coated formulation may help to improve GI tolerance) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2874863','lexi-content-ref-19078385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2874863','lexi-content-ref-19078385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Slow acetylator phenotype (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4146729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4146729'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Delayed hypersensitivity reactions may occur with sulfasalazine ranging from maculopapular <b>skin rash (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2874863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2874863'])">Ref</a></span>)</b>to severe cutaneous adverse reactions (SCARs). SCARs include <b>acute generalized exanthematous pustulosis</b>, <b>Stevens-Johnson syndrome </b>(SJS), <b>toxic epidermal necrolysis </b>(TEN), and <b>drug reaction with eosinophilia and systemic symptoms </b>(DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21592453','lexi-content-ref-33363869','lexi-content-ref-30121684','lexi-content-ref-7718014','lexi-content-ref-10405480','lexi-content-ref-34397495','lexi-content-ref-34642219','lexi-content-ref-32933910','lexi-content-ref-26757493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21592453','lexi-content-ref-33363869','lexi-content-ref-30121684','lexi-content-ref-7718014','lexi-content-ref-10405480','lexi-content-ref-34397495','lexi-content-ref-34642219','lexi-content-ref-32933910','lexi-content-ref-26757493'])">Ref</a></span>). In some cases, predominant <b>hepatotoxicity</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33363869','lexi-content-ref-18405372','lexi-content-ref-2878646','lexi-content-ref-1348259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33363869','lexi-content-ref-18405372','lexi-content-ref-2878646','lexi-content-ref-1348259'])">Ref</a></span>), pulmonary toxicity (including <b>eosinophilic pneumonitis</b>,<b> pulmonary alveolitis </b>[fibrosing], and <b>interstitial fibrosis</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1348220','lexi-content-ref-30515045','lexi-content-ref-1675246','lexi-content-ref-11999006']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1348220','lexi-content-ref-30515045','lexi-content-ref-1675246','lexi-content-ref-11999006'])">Ref</a></span>), or <b>interstitial nephritis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19509026','lexi-content-ref-11672959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19509026','lexi-content-ref-11672959'])">Ref</a></span>) is noted, although these are usually part of DRESS. Discontinuation of sulfasalazine leads to resolution of symptoms in most patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1348220','lexi-content-ref-34642219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1348220','lexi-content-ref-34642219'])">Ref</a></span>). However, in some cases of fulminant hepatitis, liver transplantation and fatalities have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9443132','lexi-content-ref-33363869','lexi-content-ref-18405372']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9443132','lexi-content-ref-33363869','lexi-content-ref-18405372'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Delayed hypersensitivity reactions: Non–dose-related, immunologic or idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18405372']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18405372'])">Ref</a></span>). SCARs are T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-34143437','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-34143437','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed hypersensitivity reactions: Varied. SCARs usually occur 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-NICE.1','lexi-content-ref-31562941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-NICE.1','lexi-content-ref-31562941'])">Ref</a></span>), but may occur more rapidly (often within 1 day) upon reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32933910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32933910'])">Ref</a></span>). Hepatotoxicity occurs within 6 weeks after sulfasalazine initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18405372']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18405372'])">Ref</a></span>). Interstitial fibrosis has occurred more than 4 years after starting sulfasalazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1348220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1348220'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity may occur in patients with a history of a hypersensitivity reaction to sulfonamide antibiotics (eg, sulfamethoxazole/trimethoprim) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20413982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20413982'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased risk of serious skin reactions in patients with rheumatoid arthritis compared to patients with inflammatory bowel disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12235076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12235076'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• DRESS is associated with HLA-B*13:01 in Chinese Han population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25303297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25303297'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• In Japanese patients, an association between HLA-A*11:01 with sulfonamide-related (including salazosulfapyridine) SCARs have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31981579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31981579'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sulfasalazine was also identified as a significant cause of SJS/TEN in registration databases from Asian countries (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29569740']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29569740'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Viral reactivation is frequently associated with sulfasalazine DRESS and relapsing course, in particular HHV-6, HHV-7, Epstein-Barr virus, and cytomegalovirus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31853592','lexi-content-ref-19514926','lexi-content-ref-31191153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31853592','lexi-content-ref-19514926','lexi-content-ref-31191153'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Autoimmune sequelae have been associated with sulfasalazine DRESS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30578426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30578426'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased toxicity in adult-onset Still disease and systemic juvenile idiopathic arthritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24782683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24782683'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F223875"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (rheumatoid arthritis: 13%; ulcerative colitis: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (ulcerative colitis: ~33%), dyspepsia (rheumatoid arthritis: 13%), gastric distress (ulcerative colitis: ~33%), nausea (rheumatoid arthritis: 19%; ulcerative colitis: ~33%), vomiting (rheumatoid arthritis: 8%; ulcerative colitis: ~33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Oligospermia (reversible; ulcerative colitis: ~33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (rheumatoid arthritis: 9%; ulcerative colitis: ~33%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (≤4%), urticaria (ulcerative colitis: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (rheumatoid arthritis: 8%), stomatitis (rheumatoid arthritis: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acquired Heinz body anemia (ulcerative colitis: ≤3%), hemolytic anemia (ulcerative colitis: ≤3%), immunoglobulin abnormality (suppression: 10%), leukopenia (rheumatoid arthritis: 3%), thrombocytopenia (rheumatoid arthritis: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (rheumatoid arthritis: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (rheumatoid arthritis: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cyanosis (ulcerative colitis: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (includes reactions reported with mesalamine or other sulfonamides):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypersensitivity myocarditis, pericarditis (with or without cardiac tamponade), polyarteritis nodosa, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, erythema multiforme, parapsoriasis varioliformis acuta, skin discoloration, skin photosensitivity</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Bloody diarrhea, diarrhea (Amos 1986), neutropenic enterocolitis, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Crystalluria, hematuria, nephrotic syndrome, proteinuria, toxic nephrosis (with oliguria and anuria), urinary tract infection, urine discoloration</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Wadelius 2018), aplastic anemia, eosinophilia, hemolytic-uremic syndrome, hypoprothrombinemia, megaloblastic anemia, methemoglobinemia, myelodysplastic syndrome, neutropenia (congenital), purpuric disease</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Fulminant hepatitis, hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Serum sickness</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Serum sickness-like reaction (children with juvenile rheumatoid arthritis have frequent and severe reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, cauda equina syndrome, depression, drowsiness, Guillain-Barre syndrome, hallucination, insomnia, meningitis, peripheral neuropathy, seizure, transverse myelitis, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, lupus-like syndrome, rhabdomyolysis, transient lesions of the posterior spinal column</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival injection, injected sclera, periorbital edema</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis (Augusto 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Eosinophilic pneumonitis (Parry 2002), pleurisy, pulmonary alveolitis (fibrosing) (Leino 1991)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (includes reactions reported with mesalamine or other sulfonamides):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Kawasaki syndrome, myocarditis (Jeremic 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Choon 2018), exfoliative dermatitis, pallor, Stevens-Johnson syndrome (Zizi 2015), toxic epidermal necrolysis (Shahidi-Dadras 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Folate deficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hematologic disease (pseudomononucleosis), purpuric rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis, cholestatic jaundice, hepatic cirrhosis, hepatic failure, hepatic necrosis, hepatotoxicity (idiosyncratic) (Chalasani 2021), jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Cildag 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Sil 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis, severe infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Intracranial hypertension (Tan 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial fibrosis (Kerget 2018), oropharyngeal pain, pneumonia</p></div>
<div class="block coi drugH1Div" id="F223889"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to sulfasalazine, its metabolites, sulfonamides, salicylates, or any component of the formulation; intestinal or urinary obstruction; porphyria</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged. See “Warnings/Precautions” for more detail.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe renal impairment (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>); severe hepatic impairment; use in pediatric patients &lt;2 years of age; patients in whom acute asthmatic attacks, urticaria, rhinitis, or other allergic manifestations are precipitated by acetyl salicylic acid (ASA) or other NSAIDs</p></div>
<div class="block war drugH1Div" id="F223872"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Deaths from irreversible neuromuscular and CNS changes have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Folate deficiency: May decrease folic acid absorption.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Serious infections (some fatal), including sepsis and pneumonia, have been reported. Infections may be associated with agranulocytosis, neutropenia, or myelosuppression. Monitor for signs/symptoms of infection during and after sulfasalazine therapy and promptly evaluate if infection occurs; discontinue therapy for serious infections. Use cautiously in patients with a history of recurring or chronic infections or with underlying conditions or concomitant therapy which may predispose them to infectious complications.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide ("sulfa") allergy: Traditionally, concerns for cross-reactivity have extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur, or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides and antibiotic sulfonamides. A nonantibiotic sulfonamide compound which contains the arylamine structure and therefore may cross-react with antibiotic sulfonamides is sulfasalazine (Zawodniak 2010). T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (SJS/TEN), some clinicians choose to avoid exposure to these classes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Allergies/asthma: Use with caution in patients with severe allergies or bronchial asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with extreme caution in patients with impaired hepatic function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Maintain adequate hydration to prevent crystalluria and stone formation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Slow acetylators: Patients classified as slow acetylators may be at increased risk for adverse reactions due to a prolonged half-life of sulfapyrazine (metabolite of sulfasalazine).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Delayed release: Use in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of GI intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites (eg, patients experiencing nausea and vomiting with the first few doses of the drug, patients in whom a reduction in dosage does not alleviate the adverse GI effects).</p>
<p style="text-indent:-2em;margin-left:4em;">• Enteric-coated tablets: Discontinue if tablets are noted to pass without disintegrating.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Skin/urine discoloration: May cause skin and urine discoloration (orange/yellow).</p></div>
<div class="block foc drugH1Div" id="F223882"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Azulfidine: 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Azulfidine: 500 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Azulfidine EN-tabs: 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p></div>
<div class="block geq drugH1Div" id="F223868"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F223891"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Azulfidine EN-tabs Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $2.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (sulfaSALAzine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.44</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Azulfidine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $1.93</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (sulfaSALAzine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.24 - $2.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868311"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Salazopyrin: 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Salazopyrin: 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p></div>
<div class="block adm drugH1Div" id="F223886"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">
<b>Oral:</b> Administer tablets in evenly divided doses, preferably after meals. Delayed-release tablets should be swallowed whole; do not chew or crush.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Delayed-release tablet should be swallowed whole. Do not chew or crush. IR tablet is available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.</p></div>
<div class="block admp drugH1Div" id="F52613889"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Tablets should be administered in evenly divided doses, preferably after meals. Do not crush enteric-coated tablets.</p></div>
<div class="block use drugH1Div" id="F223885"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile rheumatoid arthritis:</b> Delayed release: Treatment of pediatric patients with polyarticular-course juvenile rheumatoid arthritis who have responded inadequately to salicylates or other NSAIDs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis:</b> Delayed release: Treatment of rheumatoid arthritis in patients who have responded inadequately to salicylates or other NSAIDs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis, mildly to moderately active:</b> Immediate and delayed release: Treatment of mild to moderate ulcerative colitis; adjunctive therapy in severe ulcerative colitis; prolongation of the remission period between acute attacks of ulcerative colitis.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Based on the American Gastroenterological Association (AGA) guidelines on the management of moderate to severe ulcerative colitis, if remission is achieved with concomitant biologic agents or immunomodulators, sulfasalazine should not be continued for maintenance of remission (AGA [Feuerstein 2020]).</p></div>
<div class="block off-label drugH1Div" id="F25744907"><span class="drugH1">Use: Off-Label: Adult</span><p>Ankylosing spondylitis; Crohn disease, mild to moderately active; Psoriatic arthritis</p></div>
<div class="block mst drugH1Div" id="F223953"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">SulfaSALAzine may be confused with cefuroxime, salsalate, sulfADIAZINE</p>
<p style="text-indent:-2em;margin-left:4em;">Azulfidine may be confused with Augmentin, azaTHIOprine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300096"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2</p></div>
<div class="block dri drugH1Div" id="F223877"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: 5-Aminosalicylic Acid Derivatives may decrease the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: SulfaSALAzine may diminish the therapeutic effect of COVID-19 Vaccines.  Management: Rheumatology guidelines recommend holding sulfasalazine for 1 to 2 weeks after vaccine administration as permitted by the underlying disease. These guidelines consider sulfasalazine to be an immunomodulatory or immunosuppressive medication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Folic Acid: SulfaSALAzine may decrease the serum concentration of Folic Acid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: May enhance the adverse/toxic effect of SulfaSALAzine. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: SulfaSALAzine may enhance the hepatotoxic effect of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylfolate: SulfaSALAzine may decrease the serum concentration of Methylfolate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Myelosuppressive Agents: 5-Aminosalicylic Acid Derivatives may enhance the myelosuppressive effect of Myelosuppressive Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oteseconazole: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riluzole: SulfaSALAzine may enhance the adverse/toxic effect of Riluzole. Specifically, the risk of hepatotoxicity may be increased.  Management: Consider alternatives to sulfasalazine in patients receiving treatment with riluzole due to the potential for additive hepatotoxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors). Management: Monitor patients receiving rolapitant for increased exposure to and/or effects of BCRP/ABCG2 substrates.  Use the lowest effective rosuvastatin dose when used in combination with rolapitant.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafamidis: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopurine Analogs: 5-Aminosalicylic Acid Derivatives may enhance the myelosuppressive effect of Thiopurine Analogs. 5-Aminosalicylic Acid Derivatives may increase serum concentrations of the active metabolite(s) of Thiopurine Analogs. Specifically, exposure to the active 6-thioguanine nucleotides (6-TGN) may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Varicella Virus-Containing Vaccines: 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections.  Management: Avoid administration of salicylates for at least 6 weeks after adminstration of a varicella virus-containing vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): 5-Aminosalicylic Acid Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists. 5-Aminosalicylic Acid Derivatives may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53623695"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Sulfasalazine maintenance doses for the management of inflammatory bowel disease may be continued in women planning a pregnancy. A 3- to 6-month remission prior to conception reduces the risk of flare-up during pregnancy (AGA [Mahadevan 2019]). Based on available information, sulfasalazine can be continued in females with rheumatic and musculoskeletal diseases who are planning a pregnancy. Conception should be planned during a period of quiescent/low disease activity (ACR [Sammaritano 2020]). Supplementation with folic acid is recommended (ACR [Sammaritano 2020]; AGA [Mahadevan 2019]).</p>
<p style="text-indent:0em;margin-top:2em;">Sulfasalazine may cause oligospermia and reversible infertility in males; however, there is no data which suggest it would be teratogenic. Based on available information, sulfasalazine can be continued in males with rheumatic and musculoskeletal diseases who are planning to father a child. A semen analysis should be considered if conception does not occur (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F9751041"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Sulfasalazine and sulfapyridine cross the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Based on available data, an increase in fetal malformations has not been observed following maternal use of sulfasalazine for the treatment of inflammatory bowel disease. Cases of neural tube defects have been reported (causation undetermined). Agranulocytosis was noted in an infant following maternal use of sulfasalazine during pregnancy. Although sulfapyridine has poor bilirubin-displacing ability, a potential for kernicterus in the newborn exists.</p>
<p style="text-indent:0em;margin-top:2em;">Aminosalicylates may be continued at prepregnancy maintenance doses for the management of inflammatory bowel disease; however, sulfasalazine is not the preferred drug in this class for use in pregnant women (AGA [Mahadevan 2019]). Based on available information, sulfasalazine can be continued during pregnancy in females with rheumatic and musculoskeletal diseases (ACR [Sammaritano 2020]). Sulfasalazine is known to inhibit the absorption and metabolism of folic acid and may diminish the effects of folic acid supplementation. Supplementation with folic acid is recommended (ACR [Sammaritano 2020]; AGA [Mahadevan 2019]).</p></div>
<div class="block brc drugH1Div" id="F223892"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Sulfasalazine and sulfapyridine are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Sulfasalazine concentrations are insignificant; however, sulfapyridine concentrations are ~30% to 60% of the maternal serum. In one case report, sulfapyridine appeared in breast milk within 4 hours of the initial maternal dose and remained fairly constant over the dosing interval. Acetylsulfapyridine was also present in some breast milk samples (Berlin 1980).</p>
<p style="text-indent:-2em;margin-left:2em;">One episode of bloody diarrhea was first observed in a 2-month old exclusively breastfed infant. The symptoms reappeared 2 weeks later with up to 6 episodes/day, and continued until 3 months of age. The mother had been taking sulfasalazine for 5 years. Within 72 hours of discontinuing therapy, bloody stools stopped in the infant. Although maternal plasma concentrations were in the therapeutic range, the mother was determined to be a slow acetylator. Sulfapyridine was detected in the infant; milk samples were not obtained (Branski 1986). The manufacturer notes that although sulfapyridine has poor bilirubin-displacing ability, exposure may cause kernicterus in the newborn.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be exercised when administering sulfasalazine to breastfeeding women. Based on available information, sulfasalazine is considered compatible for use in females with inflammatory bowel disease or rheumatic and musculoskeletal diseases who are breastfeeding (ACR [Sammaritano 2020]; AGA [Mahadevan 2019]). However, sulfasalazine is not the preferred drug in this class for use in lactating women with inflammatory bowel disease (AGA [Mahadevan 2019]). Breastfeeding during therapy should be avoided if the infant is premature, ill, has hyperbilirubinemia, or G-6-PD deficiency. Infants should be monitored for diarrhea (WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F223893"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Sulfasalazine impairs folate absorption. Adequate fluid intake is required to prevent crystalluria and stone formation.</p></div>
<div class="block mop drugH1Div" id="F9751223"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Manufacturer's labeling: CBC with differential and LFTs (prior to therapy, then every other week for first 3 months of therapy, followed by every month for the second 3 months, then once every 3 months thereafter or as clinically indicated); periodic urinalysis and renal/LFTs; stool frequency; signs of infection, dermatologic toxicity (eg, skin rash, mucosal lesions), hypersensitivity reactions, or blood dyscrasias (eg, rash, sore throat, fever, pallor, purpura).</p>
<p style="text-indent:-2em;margin-left:2em;">Alternate recommendations: Rheumatoid arthritis: Complete blood count, serum creatinine, and LFTs: Baseline and every 2 to 4 weeks for 3 months after initiation or following dose increases, then every 8 to 12 weeks during 3 to 6 months of treatment, followed by every 12 weeks beyond 6 months of treatment; monitor more frequently if clinically indicated (ACR [Singh 2016]; ACR [Fraenkel 2021]).</p></div>
<div class="block rer drugH1Div" id="F15896591"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Sulfapyridine concentrations &gt;50 mcg/mL are associated with increased adverse events.</p></div>
<div class="block pha drugH1Div" id="F223871"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF); action appears topical rather than systemic</p></div>
<div class="block phk drugH1Div" id="F223888"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Rheumatoid arthritis: &gt;4 weeks; Ulcerative colitis: &gt;3 to 4 weeks</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Sulfasalazine: &lt;15% as parent drug</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Sulfasalazine: &gt;99% to albumin; Sulfapyridine: ~70% to albumin; Acetylsulfapyridine (AcSP): ~90% to plasma proteins</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Sulfasalazine: 7.5 ± 1.6 L</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Via colonic intestinal flora to sulfapyridine and 5-aminosalicylic acid (5-ASA). Following absorption, sulfapyridine undergoes acetylation to form AcSP and ring hydroxylation while 5-ASA undergoes N-acetylation (non-acetylation phenotype dependent process); rate of metabolism via acetylation dependent on acetylation phenotype</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Sulfasalazine: &lt;15%; Sulfapyridine: ~60%; 5-aminosalicylic acid: ~10% to 30%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Sulfasalazine: 7.6 ± 3.4 hours (prolonged in older adults); Sulfapyridine: 14.8 hours (slow acetylators) and 10.4 hours (fast acetylators)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Sulfasalazine: 3 to 12 hours (mean: 6 hours); Sulfapyridine and 5-aminosalicylic acid (5-ASA): ~10 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (as unchanged drug, conjugates, and acetylated metabolites); feces (small amounts)</p></div>
<div class="block phksp drugH1Div" id="F51221472"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Elderly patients with rheumatoid arthritis showed a prolonged plasma half-life for sulfasalazine, sulfapyridine, and their metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Acetylator status: SP metabolism is mediated by polymorphic enzymes such that 2 distinct populations of slow and fast metabolizer exist. Slow acetylator phenotype (~60% of white patients) display a prolonged plasma half-life and an accumulation of higher plasma levels of SP than fast acetylators.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F223894"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Azulfidine en-tabs | Flogostop</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Pyralin | Salazopyrin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Reumazin | Salazine | Salazopyrin | Sulfacol | Sulfazin | Zulfidin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrine | Salazopyrine ec</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin | Sulfaenterin | Sulfasalazin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Azulfin | Salazoprin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin | Salazopyrin en</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Azulfidine | Azulfidine EN | Eurozina Re</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Rosulfan | Rosulfant | Salazin | Salazopyrin | Sulfasalazina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin en | Sulfasalazin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Azulfidine | Colo-pleon | Pleon ra | Salazopyrina | Salazopyrine | Salazopyrine ra | Sulfasalazin | Sulfasalazin hexal | Sulfasalazin Heyl</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Sulfasalazin Medac</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Azulfidine</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Falazine</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin | Sulfasalasin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Colosalazine ec | Salazo | Salazopyrin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrina</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Gastropyrin | Salazopyrin | Salopyr | Sulfasalazin Medac</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin | Sulazine | Sulphasalazine | Sulphasalazine aps | Sulphasalazine dc | Ucine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Salopyrin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Pms-sulfasalazine | Salazopyrin | Saridine E | Sulphasalazine | Zopyrin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin en | Sulfasalazin | Sulfasalazin krka | Sulfasalzin Krka</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Lazafin | Sulcolon | Sulfitis</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Salazine | Salazopyrin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Dalazosaz | Iwata | Ra zin | Saaz | Salazar | Salazin | Salazopyrin | Sazo | Sazo EN | Selzotas | Zemosal</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin en</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Asasurfan | Azulfidine EN | Eminapyrin | Lanofen | Safildine en | Salazopyrin | Salazosulfapyridine | Slama | Soaresin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin en</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Azasulfan | Salazine | Salazopyrin | Salazopyrin en | Saludine | Sarazopyrin en | Saromeien | Sazopine | Seltasin | Zopyrin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin | Salazopyrin en</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin | Salazopyrine EN</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Salazidin gr | Salazopyrin | Sulfasalazin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Pleon ra | Salazopyrin | Salazopyrin en | Sulfasalazin | Sulfasalazin Heyl</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Andagun | Azulfidina | Lafasul</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Salazine | Sazo | Sazo EN</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin | Salazopyrine | Salazosulfapyr | Sulfasalazine Gf | Sulfasalazine Mylan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin | Salazopyrin en | Salazopyrine ec | Sulfasalazine ec</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Azulfidine en 500 mg | Disalazin | Galazine | Lafazin | Medisalazina | Sanroxine | Sulfasalazina</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Salazine | Salazodine | Salazopyrin | Sulfasal</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Azulfidine | Salazopyrin | Salazopyrin en | Sulfasalazin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Azulfidine | Azulfidine en-tabs | Sulfazine | Sulfazine ec</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Salazopirina | Salazopirina en</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Sulazine</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Sulfasalazin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Sulfasalazin | Sulfasalazine en | Sulfasalazine nativ</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Pms-sulfasalazine | Salazopyrin | Salazopyrin en</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin | Salazopyrin en | Salazopyrina | Sulfasalazin Medac</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Pms-sulfasalazine | Salazopyrin | Salazopyrin en</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Sulfasalazin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Sulfasalazin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Salazine | Salazopyrin | Saridine | Sulsa | Zaladine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Salasopyrine | Salazopyrine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bomecon | Salazine | Salazopyrin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin | Sulfasalazin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Azulfidine | Salazodin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Azulfidine</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Salazopyrin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24252022">
<a name="24252022"></a>Akiyama Y, Sakurai Y, Kato Y, Furuta E, Mimura T. Retrospective study of salazosulfapyridine in eight patients with rheumatoid arthritis on hemodialysis. <i>Mod Rheumatol</i>. 2014;24(2):285-290. doi:10.3109/14397595.2013.843746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/24252022/pubmed" id="24252022" target="_blank">24252022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31853592">
<a name="31853592"></a>Ammar H, Azouzi A, Fathallah N, et al. Fatal sulfasalazine-induced DRESS complicated by HHV-6 reactivation and hemophagocytic lymphohistiocytosis. <i>Eur J Clin Pharmacol</i>. 2020;76(3):467-468. doi:10.1007/s00228-019-02809-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/31853592/pubmed" id="31853592" target="_blank">31853592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2874863">
<a name="2874863"></a>Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. <i>Br Med J (Clin Res Ed)</i>. 1986;293(6544):420-423. doi:10.1136/bmj.293.6544.420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/2874863/pubmed" id="2874863" target="_blank">2874863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9561342">
<a name="9561342"></a>Ardizzone S, Porro GB. A practical guide to the management of distal ulcerative colitis. <i>Drugs. </i>1998;55(4):519-542.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/9561342/pubmed" id="9561342" target="_blank">9561342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19509026">
<a name="19509026"></a>Augusto JF, Sayegh J, Simon A, et al. A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis. <i>Nephrol Dial Transplant</i>. 2009;24(9):2940-2942. doi:10.1093/ndt/gfp277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/19509026/pubmed" id="19509026" target="_blank">19509026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6105118">
<a name="6105118"></a>Azad Khan AK, Howes DT, Piris J, Truelove SC. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. <i>Gut</i>. 1980;21(3):232-240. doi:10.1136/gut.21.3.232<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/6105118/pubmed" id="6105118" target="_blank">6105118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Azulfidine.1">
<a name="Azulfidine.1"></a>Azulfidine (sulfasalazine) [prescribing information]. New York, NY: Pfizer Labs; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Azulfidine.2">
<a name="Azulfidine.2"></a>Azulfidine EN-tabs (sulfasalazine) [prescribing information]. New York, NY: Pfizer Labs; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19514926">
<a name="19514926"></a>Balci DD, Peker E, Duran N, Dogramaci CA. Sulfasalazine-induced hypersensitivity syndrome in a 15-year-old boy associated with human herpesvirus-6 reactivation. <i>Cutan Ocul Toxicol</i>. 2009;28(1):45-47. doi:10.1080/15569520802696250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/19514926/pubmed" id="19514926" target="_blank">19514926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6108198">
<a name="6108198"></a>Berlin CM Jr, Yaffe SJ. Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk. <i>Dev Pharmacol Ther</i>. 1980;1(1):31-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/6108198/pubmed" id="6108198" target="_blank">6108198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9443132">
<a name="9443132"></a>Besnard M, Debray D, Durand P, Cézard JP, Navarro J. Sulfasalazine-induced fulminant hepatitis in pediatric Crohn's disease: report of two cases. <i>J Pediatr Gastroenterol Nutr</i>. 1998;26(1):119-120. doi:10.1097/00005176-199801000-00021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/9443132/pubmed" id="9443132" target="_blank">9443132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21452260">
<a name="21452260"></a>Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. <i>Arthritis Care Res</i>. 2011;63(4):465-482.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/21452260/pubmed" id="21452260" target="_blank">21452260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9133974">
<a name="9133974"></a>Box SA, Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. <i>Br J Rheumatol</i>. 1997;36(3):382-386. doi:10.1093/rheumatology/36.3.382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/9133974/pubmed" id="9133974" target="_blank">9133974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15303450">
<a name="15303450"></a>Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/15303450/pubmed" id="15303450" target="_blank">15303450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2870147">
<a name="2870147"></a>Branski D, Kerem E, Gross-Kieselstein E, Hurvitz H, Litt R, Abrahamov A. Bloody diarrhea--a possible complication of sulfasalazine transferred through human breast milk.<i> J Pediatr Gastroenterol Nutr</i>. 1986;5(2):316-317.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/2870147/pubmed" id="2870147" target="_blank">2870147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21630245">
<a name="21630245"></a>Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. <i>Arthritis Rheum</i>. 2011;63(6):1543-1551.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/21630245/pubmed" id="21630245" target="_blank">21630245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21592453">
<a name="21592453"></a>Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. <i>Am J Med</i>. 2011;124(7):588-597. doi:10.1016/j.amjmed.2011.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/21592453/pubmed" id="21592453" target="_blank">21592453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33363869">
<a name="33363869"></a>Calil IL, Tustumi F, Pinheiro RSN, et al. Liver transplantation after DRESS syndrome: a case report and review of the literature. <i>Clin Case Rep</i>. 2020;8(12):3008-3012. doi:10.1002/ccr3.3334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/33363869/pubmed" id="33363869" target="_blank">33363869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17551063">
<a name="17551063"></a>Cantarini L, Tinazzi I, Biasi D, Fioravanti A, Galeazzi M. Sulfasalazine-induced immune thrombocytopenia. <i>Postgrad Med J</i>. 2007;83(980):e1. doi:10.1136/pgmj.2006.055194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/17551063/pubmed" id="17551063" target="_blank">17551063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30121684">
<a name="30121684"></a>Choon SE, Der YS, Lai NLJ, Yu SEE, Yap XL, Nalini NM. Clinical characteristics, culprit drugs and outcome of patients with Acute Generalised Exanthematous Pustulosis seen in Hospital Sultanah Aminah, Johor Bahru. <i>Med J Malaysia</i>. 2018;73(4):220-225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/30121684/pubmed" id="30121684" target="_blank">30121684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28121807">
<a name="28121807"></a>Cildag S, Senturk T. Sulfasalazine-related hypersensitivity reactions in patients with rheumatic diseases. <i>J Clin Rheumatol</i>. 2017;23(2):77-79. doi:10.1097/RHU.0000000000000490<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/28121807/pubmed" id="28121807" target="_blank">28121807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10555027">
<a name="10555027"></a>Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. <i>Arthritis Rheum</i>. 1999;42(11):2325-2329.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/10555027/pubmed" id="10555027" target="_blank">10555027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8961906">
<a name="8961906"></a>Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs cooperative study. <i>Arthritis Rheum</i>. 1996;39(12):2013-2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/8961906/pubmed" id="8961906" target="_blank">8961906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26749174">
<a name="26749174"></a>Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. <i>Arthritis Rheumatol</i>. 2016;68(5):1060-1071.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/26749174/pubmed" id="26749174" target="_blank">26749174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4146729">
<a name="4146729"></a>Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. <i>N Engl J Med</i>. 1973;289(10):491-495. doi:10.1056/NEJM197309062891001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/4146729/pubmed" id="4146729" target="_blank">4146729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21982969">
<a name="21982969"></a>DeMichele J, Rezaizadeh H, Goldstein JI. Sulfasalazine crystalluria-induced anuric renal failure. <i>Clin Gastroenterol Hepatol</i>. 2012;10(2):A32. doi:10.1016/j.cgh.2011.09.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/21982969/pubmed" id="21982969" target="_blank">21982969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34143437">
<a name="34143437"></a>Deshpande P, Hertzman RJ, Palubinsky AM, et al. Immunopharmacogenomics: mechanisms of HLA-associated drug reactions. <i>Clin Pharmacol Ther</i>. 2021;110(3):607-615. doi:10.1002/cpt.2343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/34143437/pubmed" id="34143437" target="_blank">34143437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4150435">
<a name="4150435"></a>Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). <i>Gut</i>. 1973;14(12):923-926. doi:10.1136/gut.14.12.923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/4150435/pubmed" id="4150435" target="_blank">4150435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7748217">
<a name="7748217"></a>Dougados M, vam der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. <i>Arthritis Rheum</i>. 1995;38(5):618-627.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/7748217/pubmed" id="7748217" target="_blank">7748217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669550">
<a name="28669550"></a>Durando M, Tiu H, Kim JS. Sulfasalazine-induced crystalluria causing severe acute kidney injury. <i>Am J Kidney Dis</i>. 2017;70(6):869-873. doi:10.1053/j.ajkd.2017.05.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/28669550/pubmed" id="28669550" target="_blank">28669550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25854308">
<a name="25854308"></a>Fathallah N, Slim R, Rached S, Hachfi W, Letaief A, Ben Salem C. Sulfasalazine-induced DRESS and severe agranulocytosis successfully treated by granulocyte colony-stimulating factor. <i>Int J Clin Pharm</i>. 2015;37(4):563-565. doi:10.1007/s11096-015-0107-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/25854308/pubmed" id="25854308" target="_blank">25854308</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. <i>Gastroenterology</i>. 2020;158(5):1450-1461. doi:10.1053/j.gastro.2020.01.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/31945371/pubmed" id="31945371" target="_blank">31945371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21407188">
<a name="21407188"></a>Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2011;106(4):601-616. doi:10.1038/ajg.2011.67<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/21407188/pubmed" id="21407188" target="_blank">21407188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34101387">
<a name="34101387"></a>Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(7):924-939. doi:10.1002/acr.24596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/34101387/pubmed" id="34101387" target="_blank">34101387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7567188">
<a name="7567188"></a>Giannini EH, Cawkwell GD. Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future. <i>Pediatr Clin North Am.</i> 1995;42(5):1099-1125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/7567188/pubmed" id="7567188" target="_blank">7567188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31191153">
<a name="31191153"></a>Girijala RL, Ramamurthi A, Wright D, Kwak Y, Goldberg LH. DRESS syndrome associated with influenza virus. <i>Proc (Bayl Univ Med Cent)</i>. 2019;32(2):277-278. doi:10.1080/08998280.2019.1576094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/31191153/pubmed" id="31191153" target="_blank">31191153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17243140">
<a name="17243140"></a>Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. <i>Inflamm Bowel Dis</i>. 2007;13(5):629-638. doi:10.1002/ibd.20099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/17243140/pubmed" id="17243140" target="_blank">17243140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8587078">
<a name="8587078"></a>Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. <i>J Rheumatol</i>. 1995;22(5):894-898.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/8587078/pubmed" id="8587078" target="_blank">8587078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16123497">
<a name="16123497"></a>Haas RM, Li P, and Chu JW, “Glucose-Lowering Effects of Sulfasalazine in Type 2 Diabetes,” <i>Diabetes Care</i>, 2005, 28(9):2238-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/16123497/pubmed" id="16123497" target="_blank">16123497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2871549">
<a name="2871549"></a>Haines JD, Jr, “Hepatotoxicity After Treatment With Sulfasalazine,” <i>Postgrad Med</i>, 1986, 79(6):193-4, 197-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/2871549/pubmed" id="2871549" target="_blank">2871549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1348220">
<a name="1348220"></a>Hamadeh MA, Atkinson J, Smith LJ. Sulfasalazine-induced pulmonary disease. <i>Chest</i>. 1992;101(4):1033-1037. doi:10.1378/chest.101.4.1033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/1348220/pubmed" id="1348220" target="_blank">1348220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22080212">
<a name="22080212"></a>Inami Y, Yamaji K, Sato M, et al. Effects of dialysis on the pharmacokinetics of salazosulfapyridine. <i>Rheumatol Int</i>. 2013;33(2):535-539. doi:10.1007/s00296-011-2179-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/22080212/pubmed" id="22080212" target="_blank">22080212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25531204">
<a name="25531204"></a>Jeremic I, Vujasinovic-Stupar N, Terzic T, Damjanov N, Nikolic M, Bonaci-Nikolic B. Fatal sulfasalazine-induced eosinophilic myocarditis in a patient with periodic fever syndrome. <i>Med Princ Pract</i>. 2015;24(2):195-197. doi:10.1159/000369584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/25531204/pubmed" id="25531204" target="_blank">25531204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7624265">
<a name="7624265"></a>Jick H, Myers MW, and Dean AD, “The Risk of Sulfasalazine- and Mesalazine-Associated Blood Disorders,” <i>Pharmacotherapy</i>, 1995, 15(2):176-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/7624265/pubmed" id="7624265" target="_blank">7624265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18405372">
<a name="18405372"></a>Jobanputra P, Amarasena R, Maggs F, et al. Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events. <i>BMC Musculoskelet Disord</i>. 2008;9:48. doi:10.1186/1471-2474-9-48<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/18405372/pubmed" id="18405372" target="_blank">18405372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644481">
<a name="15644481"></a>Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in<i> Ann Pharmacother</i>. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/15644481/pubmed" id="15644481" target="_blank">15644481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7718014">
<a name="7718014"></a>Jullien D, Wokenstein P, Roupie E, et al. Toxic epidermal necrolysis after sulfasalazine treatment of mild psoriatic arthritis: warning on the use of sulfasalazine for a new indication. <i>Arthritis Rheum</i>, 1995;38(4):573.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/7718014/pubmed" id="7718014" target="_blank">7718014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27025798">
<a name="27025798"></a>Kato M, Kano Y, Sato Y, Shiohara T. Severe agranulocytosis in two patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. <i>Acta Derm Venereol</i>. 2016;96(6):842-843. doi:10.2340/00015555-2420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/27025798/pubmed" id="27025798" target="_blank">27025798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10405480">
<a name="10405480"></a>Kawaguchi M, Mitsuhashi Y, Kondo S. Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis. <i>J Dermatol</i>. 1999;26(6):359-362. doi:10.1111/j.1346-8138.1999.tb03488.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/10405480/pubmed" id="10405480" target="_blank">10405480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1358622">
<a name="1358622"></a>Keisu M, Ekman E. Sulfasalazine associated agranulocytosis in Sweden 1972-1989. Clinical features, and estimation of its incidence. <i>Eur J Clin Pharmacol</i>. 1992;43(3):215-218. doi:10.1007/BF02333012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/1358622/pubmed" id="1358622" target="_blank">1358622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30515045">
<a name="30515045"></a>Kerget B, Araz O, Ucar EY, Aydin O, Akgun M, Saglam L. Sulfasalazine-induced interstitial fibrosis. <i>Eurasian J Med</i>. 2018;50(3):207-209. doi:10.5152/eurasianjmed.2018.17302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/30515045/pubmed" id="30515045" target="_blank">30515045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30576644">
<a name="30576644"></a>Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. <i>Gastroenterology</i>. 2019;156(3):748-764. doi:10.1053/j.gastro.2018.12.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/30576644/pubmed" id="30576644" target="_blank">30576644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11672959">
<a name="11672959"></a>Lau G, Kwan C, Chong SM. The 3-week sulphasalazine syndrome strikes again. <i>Forensic Sci Int</i>. 2001;122(2-3):79-84. doi:10.1016/s0379-0738(01)00476-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/11672959/pubmed" id="11672959" target="_blank">11672959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1675246">
<a name="1675246"></a>Leino R, Liippo K, Ekfors T. Sulphasalazine-induced reversible hypersensitivity pneumonitis and fatal fibrosing alveolitis: report of two cases. <i>J Intern Med</i>. 1991;229(6):553-556. doi:10.1111/j.1365-2796.1991.tb00396.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/1675246/pubmed" id="1675246" target="_blank">1675246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30578426">
<a name="30578426"></a>Lian BS, Busmanis I, Lee HY. Relapsing course of sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) complicated by Alopecia Universalis and Vitiligo. <i>Ann Acad Med Singap</i>. 2018;47(11):492-493.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/30578426/pubmed" id="30578426" target="_blank">30578426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610508">
<a name="29610508"></a>Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn's disease in adults. <i>Am J Gastroenterol</i>. 2018;113(4):481-517. doi: 10.1038/ajg.2018.27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/29610508/pubmed" id="29610508" target="_blank">29610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27372735">
<a name="27372735"></a>Lim WC, Wang Y, MacDonald JK, et al. Aminosalicylates for induction of remission or response in Crohn's disease. <i>Cochrane Database Syst Rev</i>. 2016;7:CD008870. doi: 10.1002/14651858.CD008870.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/27372735/pubmed" id="27372735" target="_blank">27372735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2878646">
<a name="2878646"></a>MacGilchrist AJ, Hunter JA. Sulphasalazine hepatotoxicity: lack of a hypersensitivity response. <i>Ann Rheum Dis</i>. 1986;45(11):967-968. doi:10.1136/ard.45.11.967<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/2878646/pubmed" id="2878646" target="_blank">2878646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30948039">
<a name="30948039"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD parenthood project working group. <i>Am J Obstet Gynecol</i>. 2019;220(4):308‐323. doi:10.1016/j.ajog.2019.02.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/30948039/pubmed" id="30948039" target="_blank">30948039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1348259">
<a name="1348259"></a>Marinos G, Riley J, Painter DM, McCaughan GW. Sulfasalazine-induced fulminant hepatic failure. <i>J Clin Gastroenterol</i>. 1992;14(2):132-135. doi:10.1097/00004836-199203000-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/1348259/pubmed" id="1348259" target="_blank">1348259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31981579">
<a name="31981579"></a>Nakamura R, Ozeki T, Hirayama N, et al. Association of HLA-A*11:01 with sulfonamide-related severe cutaneous adverse reactions in Japanese patients. <i>J Invest Dermatol</i>. 2020;140(8):1659-1662.e6. doi:10.1016/j.jid.2019.12.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/31981579/pubmed" id="31981579" target="_blank">31981579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27778097">
<a name="27778097"></a>Narayan N, Rigby S, Carlucci F. Sulfasalazine induced immune thrombocytopenia in a patient with rheumatoid arthritis. <i>Clin Rheumatol</i>. 2017;36(2):477-479. doi:10.1007/s10067-016-3420-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/27778097/pubmed" id="27778097" target="_blank">27778097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>NICE. Clinical guideline 183. Drug allergy: diagnosis and management of drug allergy in adults, children and young people. 2014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/NICE.1/pubmed" id="NICE.1" target="_blank">NICE.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9710881">
<a name="9710881"></a>O'Dell JR, “Triple Therapy With Methotrexate, Sulfasalazine, and Hydroxychloroquine in Patients With Rheumatoid Arthritis,” <i>Rheum Dis Clin North Am</i>, 1998, 24(3):465-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/9710881/pubmed" id="9710881" target="_blank">9710881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11999006">
<a name="11999006"></a>Parry SD, Barbatzas C, Peel ET, Barton JR. Sulphasalazine and lung toxicity. <i>Eur Respir J</i>. 2002;19(4):756-764. doi:10.1183/09031936.02.00267402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/11999006/pubmed" id="11999006" target="_blank">11999006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12235076">
<a name="12235076"></a>Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. <i>Gut</i>. 2002;51(4):536-539. doi:10.1136/gut.51.4.536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/12235076/pubmed" id="12235076" target="_blank">12235076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24092554">
<a name="24092554"></a>Ringold S, Weiss PF, Beukelman T, et al; American College of Rheumatology. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. <i>Arthritis Rheum</i>. 2013;65(10):2499-2512. doi: 10.1002/art.38092.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/24092554/pubmed" id="24092554" target="_blank">24092554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20227029">
<a name="20227029"></a>Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. <i>Best Pract Res Clin Gastroenterol</i>. 2010;24(2):157-165. doi:10.1016/j.bpg.2009.10.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/20227029/pubmed" id="20227029" target="_blank">20227029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30840605">
<a name="30840605"></a>Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. <i>Am J Gastroenterol</i>. 2019;114(3):384-413. doi:10.14309/ajg.0000000000000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/30840605/pubmed" id="30840605" target="_blank">30840605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22516861">
<a name="22516861"></a>Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. <i>J Pediatr Gastroenterol Nutr</i>. 2012;55(1):93-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/22516861/pubmed" id="22516861" target="_blank">22516861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SalazopyrinCAN.1">
<a name="SalazopyrinCAN.1"></a>Salazopyrin (sulfasalazine tablets) Salazopyrin En-tabs (sulfasalazine delayed-release tablets) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SalazopyrinCAN.2">
<a name="SalazopyrinCAN.2"></a>Salazopyrin (sulfasalazine) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; November 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529‐556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17877506">
<a name="17877506"></a>Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. <i>Aliment Pharmacol Ther</i>. 2007;26(7):987-1003. doi: 10.1111/j.1365-2036.2007.03455.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/17877506/pubmed" id="17877506" target="_blank">17877506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20081543">
<a name="20081543"></a>Sandhu BK, Fell JME, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. <i>JPGN</i>. 2010;50:1-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/20081543/pubmed" id="20081543" target="_blank">20081543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34397495">
<a name="34397495"></a>Shahidi-Dadras M, Shahrigharahkoshan S, Yazdi E, Fatemi A, Mahboubi-Fooladi Z, Dadkhahfar S. Sulfasalazine-induced toxic epidermal necrolysis: a challenging case during the COVID-19 pandemic. <i>Adv Emerg Nurs J</i>. 2021;43(3):194-197. doi:10.1097/TME.0000000000000361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/34397495/pubmed" id="34397495" target="_blank">34397495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34642219">
<a name="34642219"></a>Sil A, Bhattacharjee MS, Chandra A, Pramanik JD. Sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) with concomitant acute chikungunya virus infection: possible role of new viral trigger. <i>BMJ Case Rep</i>. 2021;14(10):e244063. doi:10.1136/bcr-2021-244063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/34642219/pubmed" id="34642219" target="_blank">34642219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26545940">
<a name="26545940"></a>Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Rheumatol</i>. 2016;68(1):1-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/26545940/pubmed" id="26545940" target="_blank">26545940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242722">
<a name="15242722"></a>Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/15242722/pubmed" id="15242722" target="_blank">15242722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31562941">
<a name="31562941"></a>Soria A, Bernier C, Veyrac G, Barbaud A, Puymirat E, Milpied B. Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: a retrospective study. <i>J Am Acad Dermatol</i>. 2020;82(3):606-611. doi:10.1016/j.jaad.2019.09.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/31562941/pubmed" id="31562941" target="_blank">31562941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31969328">
<a name="31969328"></a>Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Ann Rheum Dis</i>. 2020;79(6):685-699. doi:10.1136/annrheumdis-2019-216655<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/31969328/pubmed" id="31969328" target="_blank">31969328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24782683">
<a name="24782683"></a>Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. <i>Pediatr Rheumatol Online J</i>. 2014;12:13. doi:10.1186/1546-0096-12-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/24782683/pubmed" id="24782683" target="_blank">24782683</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sulfasalazine delayed-release tablet [prescribing information]. Huntsville, AL: Qualitest Pharmaceuticals; August 2016.</div>
</li>
<li>
<div class="reference">
                  Sulfasalazine tablet [prescribing information]. Parsippany, NJ: Actavis Pharma, Inc.; December 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31741184">
<a name="31741184"></a>Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes. <i>Am J Clin Dermatol</i>. 2020;21(2):163-172. doi:10.1007/s40257-019-00485-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/31741184/pubmed" id="31741184" target="_blank">31741184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10775222">
<a name="10775222"></a>Teplitsky V, Virag I, Halabe A. Immune complex haemolytic anaemia associated with sulfasalazine. <i>BMJ</i>. 2000;320(7242):1113<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/10775222/pubmed" id="10775222" target="_blank">10775222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12795783">
<a name="12795783"></a>Teshima D, Hino B, Makino K, et al. Sulphasalazine-induced leucopenia in a patient with renal dysfunction. <i>J Clin Pharm Ther</i>. 2003;28(3):239-242. doi:10.1046/j.1365-2710.2003.00484.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/12795783/pubmed" id="12795783" target="_blank">12795783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15373844">
<a name="15373844"></a>Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/15373844/pubmed" id="15373844" target="_blank">15373844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30044357">
<a name="30044357"></a>Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;67(2):257-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/30044357/pubmed" id="30044357" target="_blank">30044357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9588731">
<a name="9588731"></a>van Rossum MA, Fiselier TJ, Franssen MJ, et al, “Sulfasalazine in the Treatment of Juvenile Chronic Arthritis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Dutch Juvenile Chronic Arthritis Study Group,” <i>Arthritis Rheum</i>, 1998, 41(5):808-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/9588731/pubmed" id="9588731" target="_blank">9588731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15188168">
<a name="15188168"></a>Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. <i>Gastroenterology</i>. 2004;126(7):1733-1739. doi:10.1053/j.gastro.2004.03.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/15188168/pubmed" id="15188168" target="_blank">15188168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7788157">
<a name="7788157"></a>Veale DJ, Ho M, and Morley KD, “Sulfasalazine-Induced Lupus in Psoriatic Arthritis,” <i>Br J Rheumatol</i>, 1995, 34(4):383-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/7788157/pubmed" id="7788157" target="_blank">7788157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28762467">
<a name="28762467"></a>Wadelius M, Eriksson N, Kreutz R, et al. Sulfasalazine-induced agranulocytosis is associated with the human leukocyte antigen locus. <i>Clin Pharmacol Ther</i>. 201;103(5):843-853. doi:10.1002/cpt.805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/28762467/pubmed" id="28762467" target="_blank">28762467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29569740">
<a name="29569740"></a>Wang YH, Chen CB, Tassaneeyakul W, et al. The medication risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in Asians: the major drug causality and comparison with the US FDA label. <i>Clin Pharmacol Ther</i>. 2019;105(1):112-120. doi:10.1002/cpt.1071<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/29569740/pubmed" id="29569740" target="_blank">29569740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26401991">
<a name="26401991"></a>Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. <i>Arthritis Rheumatol</i>. 2016;68(2):282-298.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/26401991/pubmed" id="26401991" target="_blank">26401991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19078385">
<a name="19078385"></a>Weaver A, Chatwell R, Churchill M, et al. Improved gastrointestinal tolerance and patient preference of enteric-coated sulfasalazine versus uncoated sulfasalazine tablets in patients with rheumatoid arthritis. <i>J Clin Rheumatol</i>. 1999;5(4):193-200. doi:10.1097/00124743-199908000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/19078385/pubmed" id="19078385" target="_blank">19078385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32933910">
<a name="32933910"></a>Winward J, Lyckholm L, Brown SM, Mokadem M. Case of relapsing sulfasalazine-induced hypersensitivity syndrome upon re-exposure. <i>BMJ Case Rep</i>. 2020;13(9):e235803. doi:10.1136/bcr-2020-235803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/32933910/pubmed" id="32933910" target="_blank">32933910</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25303297">
<a name="25303297"></a>Yang F, Gu B, Zhang L, et al. HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population. <i>Pharmacogenomics</i>. 2014;15(11):1461-1469. doi:10.2217/pgs.14.69<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/25303297/pubmed" id="25303297" target="_blank">25303297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20701405">
<a name="20701405"></a>Youngster I, Arcavi L, Schechmaster R, et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. <i>Drug Saf</i>. 2010;33(9):713-726. doi:10.2165/11536520-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/20701405/pubmed" id="20701405" target="_blank">20701405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20413982">
<a name="20413982"></a>Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. <i>Int Arch Allergy Immunol</i>. 2010;153(2):152-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/20413982/pubmed" id="20413982" target="_blank">20413982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26757493">
<a name="26757493"></a>Zizi N, Elmrahi A, Dikhaye S, Fihmi N, Alami Z. Stevens Johnson syndrome-toxic epidermal necrolysis overlap induced by sulfasalazine treatment: a case report. <i>Tunis Med</i>. 2015;93(7):413-415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/26757493/pubmed" id="26757493" target="_blank">26757493</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9963 Version 360.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
